Figure 2.
Kaplan‐Meier estimates of the probability of (A) progression‐free survival and (B) overall survival for the 65 long‐term survivors according to nivolumab treatment duration
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.